Modulation Therapeutics Overview
- Year Founded
-
2011
- Status
-
Private
- Latest Deal Type
-
Later Stage VC
- Investors
-
8
Modulation Therapeutics General Information
Description
Operator of a biotechnology company intended to develop therapies to defeat aggressive forms of solid tumor cancers and liver disease. The company's service includes drug discovery, development, trials, and cancer research services, enabling researchers to get the required tools and techniques to conduct research work and discover drugs.
Contact Information
Website
www.modulationtherapeutics.comCorporate Office
- 64 Medical Center Drive
- WVU Cancer Center - Room 1817
- Morgantown, WV 26506
- United States
Corporate Office
- 64 Medical Center Drive
- WVU Cancer Center - Room 1817
- Morgantown, WV 26506
- United States
Modulation Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 10. Later Stage VC | Completed | Clinical Trials - Phase 1 | ||||
| 9. Grant | 01-Jan-2019 | Completed | Startup | |||
| 8. Grant | 18-Sep-2018 | Completed | Startup | |||
| 7. Grant | 25-Sep-2017 | Completed | Startup | |||
| 6. Grant | 28-Aug-2017 | Completed | Startup | |||
| 5. Grant | 05-Mar-2016 | Completed | Startup | |||
| 4. Grant | 01-Jan-2015 | Completed | Startup | |||
| 3. Accelerator/Incubator | 14-Feb-2013 | Completed | Startup | |||
| 2. Accelerator/Incubator | 31-Aug-2012 | $156K | $156K | Completed | Startup | |
| 1. Grant | 07-Jun-2012 | $500K | Completed | Startup |
Modulation Therapeutics Patents
Modulation Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| EP-3801592-A2 | Cyclic peptide compounds and methods of use thereof | Pending | 05-Jun-2018 | ||
| CA-3102630-A1 | Cyclic peptide compounds and methods of use thereof | Pending | 05-Jun-2018 | ||
| US-20210347826-A1 | Cyclic peptide compounds and methods of use thereof | Active | 05-Jun-2018 | ||
| EP-3801592-A4 | Cyclic peptide compounds and methods of use thereof | Pending | 05-Jun-2018 | ||
| US-12060438-B2 | Cyclic peptide compounds and methods of use thereof | Active | 05-Jun-2018 | C07K7/64 |
Modulation Therapeutics Investors (8)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| National Institutes of Neurological Disorders and Stroke | Government | |||
| National Cancer Institute | Government | |||
| National Institutes of Health | Government | |||
| U.S. Department of Health and Human Services | Government | |||
| Institute for Commercialization of Florida Technology | Not-For-Profit Venture Capital | Minority |
Modulation Therapeutics FAQs
-
When was Modulation Therapeutics founded?
Modulation Therapeutics was founded in 2011.
-
Where is Modulation Therapeutics headquartered?
Modulation Therapeutics is headquartered in Morgantown, WV.
-
What industry is Modulation Therapeutics in?
Modulation Therapeutics’s primary industry is Biotechnology.
-
Is Modulation Therapeutics a private or public company?
Modulation Therapeutics is a Private company.
-
What is Modulation Therapeutics’s current revenue?
The current revenue for Modulation Therapeutics is .
-
How much funding has Modulation Therapeutics raised over time?
Modulation Therapeutics has raised $156K.
-
Who are Modulation Therapeutics’s investors?
National Institutes of Neurological Disorders and Stroke, National Cancer Institute, National Institutes of Health, U.S. Department of Health and Human Services, and Institute for Commercialization of Florida Technology are 5 of 8 investors who have invested in Modulation Therapeutics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
